Evidence map›Paper›PMID 41783776›Full record

ArticleTherapeutic advances in medical oncology2026

Impact of race/ethnicity and the presence of immune-related adverse events on outcomes for non-small cell lung cancer patients treated with immune checkpoint inhibitors.

Robert Hsu, Karen Resnick, Peter Zang, Travis Larsen, Shirley Ye, April Choi, Shawn Yu, Kevin Brady, Trevor E Angell, Lily Dara and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in medical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Robert HsuDivision of Oncology, Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA 90089-0001, USA.ORCID https://orcid.org/0000-0003-3957-6106
Karen ResnickDepartment of Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA, USA.
Peter ZangDepartment of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Travis LarsenDivision of Infectious Disease, Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
Shirley YeDepartment of Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA, USA.
April ChoiDivision of Hematology/Oncology, Department of Medicine, University of California Irvine Chao Family Comprehensive Cancer Center, Irvine, CA, USA.
Shawn YuDivision of Hematology/Oncology, Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID https://orcid.org/0000-0003-1951-2949
Kevin BradyLos Angeles General Medical Center, Los Angeles, CA, USA.
Trevor E AngellDivision of Endocrinology, Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA, USA.
Lily DaraUniversity of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
Fumito ItoUniversity of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
Jorge J NievaDivision of Medical Oncology, Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA, USA.
Gino K InDivision of Medical Oncology, Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA, USA.ORCID https://orcid.org/0000-0002-7060-5123

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026
$181.4M
Lung Cancer Early Detection and Immunotherapy Response Prediction and Monitoring with an Exo-PROS Liquid Biopsy AssayR01CA272827 · NCI · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI DY, GRACE, ITO, FUMITO · 2022 to 2025
$3.1M
In situ radioimmunotherapy to maximize the engagement of conventional type 1 dendritic cells against non-T cell-inflamed tumorsR01CA255240 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ITO, FUMITO · 2021 to 2025
$2.0M
NCI NIH HHS P30 CA014089NCI NIH HHS R01 CA255240NCI NIH HHS R01 CA272827
6 · The paper itself

Abstract

Background: Immune checkpoint inhibitors (ICIs) have changed the treatment landscape for non-small cell lung cancer, but the role of race/ethnicity is not well understood. Design: This is a retrospective study of non-small cell lung cancer (NSCLC) patients receiving ICI. Objective: We evaluated the role of race/ethnicity in ICI response and immune-related adverse events (irAEs) in NSCLC patients. Methods: NSCLC patients treated with ICIs from 2014 to 2022 at Los Angeles General Medical Center and Norris Comprehensive Cancer Center were included. Primary endpoints were irAE incidence, time on ICI treatment (TOT), overall survival (OS), and progression-free survival (PFS). TOT, OS, and PFS were evaluated using the Kaplan-Meier method. Landmark analysis was performed of patients receiving >6 month ICIs. Fisher's exact test was performed for analysis of variables between groups. Results: In total, 211 NSCLC patients receiving ICIs were analyzed, including 86 (40.8%) Asian American/Pacific Islander (AAPI), 65 (30.8%) non-Hispanic White/Caucasian (NHW), 37 (17.5%) Hispanic/Latino (HIS), and 23 (10.9%) African American/Black (AA). Among stage IV patients, median OS for AAPI was 23.2 months (95% confidence interval (CI) 16.0-not reached (NR)), 23.6 months (95% CI 6.9-38.8) for NHW, 12.7 months for AA (95% CI 2.2-37.0), and 11.0 months (95% CI 4.8-14.8) for HIS ( Conclusion: Our study demonstrates that AAPIs and NHW had higher irAE incidence and longer OS. Validation studies evaluating the role of race/ethnicity in ICI response and toxicity are merited.

Indexed as

ethnicityimmune checkpoint inhibitorsirAEnon-small cell lung cancerNSCLC

Identifiers

PMID41783776
PMCPMC12953965

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.